WO2000007583A2 - Treatment of addiction and addiction-related behavior - Google Patents
Treatment of addiction and addiction-related behavior Download PDFInfo
- Publication number
- WO2000007583A2 WO2000007583A2 PCT/US1999/017220 US9917220W WO0007583A2 WO 2000007583 A2 WO2000007583 A2 WO 2000007583A2 US 9917220 W US9917220 W US 9917220W WO 0007583 A2 WO0007583 A2 WO 0007583A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gvg
- use according
- nicotine
- cocaine
- drugs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Definitions
- This invention relates to the use of an irreversible inhibitor of GAB A- transaminase for the treatment of substance addiction and modification of behavior associated with substance addiction.
- Substance addiction such as drug abuse, and the resulting addiction-related behavior are enormous social and economic problems that continue to grow with devastating consequences.
- Substance addiction can occur by use of legal and illegal substances. Nicotine, cocaine, amphetamine, methamphetamine, eth.anol, heroin, morphine and other addictive substances are readily available and routinely used by large segments of the
- DA dopamine
- addicting drugs such as nicotine, cocaine, amphetamine, methamphetamine, ethanol, heroin, and mo ⁇ hine enhance (in some cases directly, in other cases indirectly or even trans-synaptically) dopamine (DA) within the mesotel encephalic reward/reinforcement circuitry of the forebrain, presumably producing the enhanced brain reward that constitutes the drug user's "high.”
- Alterations in the function of these DA systems have also been implicated in drug craving and in relapse to the drug-taking habit in recovering addicts.
- cocaine acts on these DA systems by binding to the dopamine transporter (DAT) and preventing DA reuptake into the presyna tic terminal.
- DAT dopamine transporter
- one treatment strategy was to target directly the DAT with a high-affinity cocaine analog, thereby blocking cocaine's binding.
- Another treatment strategy was to modulate synaptic DA directly by the use of DA agonists or antagonists.
- Yet another treatment strategy was to modulate synaptic DA, indirectly or trans-synaptically, by specifically targeting a functionally-linked but biochemically different neurotransmitter system.
- Agonists are not preferred therapeutic agents.
- a given agonist may act on several receptors, or similar receptors on different cells, not just on the particular receptor or cell one desires to stimulate.
- tolerance to a drug develops (through changes in the number of receptors and their affinity for the drug), tolerance to the agonist may likewise develop.
- a particular problem with the agonist bromocriptine, for example, is that it may itself create a drug dependency. Thus, treatment strategies used in the past did not relieve the patient's craving for cocaine. Moreover, by using certain agonists such as bromocriptine, a patient was likely to replace one craving for another.
- the alkaloid (-)-nicotine is present in cigarettes and other tobacco products that are smoked or chewed. It has been found that nicotine contributes to various diseases, including cancer, heart disease, respiratory disease and other conditions, for which tobacco use is a risk factor, particularly heart disease. Vigorous campaigns against the use of tobacco or nicotine have taken place, and it is now common knowledge that the cessation of tobacco use brings with it numerous unpleasant withdrawal symptoms, which include irritability, anxiety, restlessness, lack of concentration, lightheadedness, insomnia, tremor, increased hunger and weight gain, and, of course, an intense craving for tobacco.
- NACC nucleus accumbens
- VTA ventral segmental area
- nicotine substitution therapy such as nicotine gum, transdermal nicotine patches, nasal sprays, nicotine inhalers and bupropion, the first nonnicotinic treatment for smoking cessation (Henningfield, 1995; Hurt, et al., 1997).
- nicotine substitution therapy involves the administration of the nicotine which frequently leads to nicotine withdrawal and subsequent relapse to use of tobacco products.
- a therapy having a desirable side effect profile to relieve nicotine withdrawal symptoms, including the long term cravings for nicotine.
- narcotic analgesics such as mo ⁇ hine, heroin and other opioids both natural and semisynthetic.
- Abuse of opioids induce tolerance and dependence. Withdrawal symptoms from the cessation of opioids use vary greatly in intensity depending on numerous factors including the dose of the opioid used, the degree to which the opioid effects on the CNS are continuously exerted, the duration of chronic use, and the rate at which the opioid is removed from the receptors.
- withdrawal symptoms include craving, anxiety, dysphoria, yawning, perspiration, lacrimation, rhinorrhoea, restless and broken sleep, irritability, dilated pupils, aching of bones, back and muscles, piloerection, hot and cold flashes, nausea, vomiting, diarrhea, weight loss, fever, increased blood pressure, pulse and respiratory rate, twitching of muscles and kicking movements of the lower extremities.
- Medical complications associated with injection of opioids include a variety of pathological changes in the CNS including degenerative changes in globus pallidus, necrosis of spinal gray matter, transverse myelitis, amblyopia, plexitis, peripheral neuropathy, Parkinsonian syndromes, intellectual impairment, personality changes, and pathological changes in muscles and peripheral nerves.
- Infections of skin and systemic organs are also quite common including staphylococcal pneumonitis, tuberculosis, endocarditis, septicemia, viral hepatitis, human immunodeficiency virus
- HAV hypertension
- tetanus tetanus
- osteomyelitis The life expectancy of opioid addicts is markedly reduced, due to overdose, drug-related infections, suicide and homicide.
- opioid dependence Pharmaceutical agents used in treating opioid dependence include methadone, which is an opioid, and opioid antagonists, primarily naloxone and naltrexone. Clonidine has been shown to suppress some elements of opioid withdrawal but suffers from the side effects of hypotension and sedation, which can be quite extreme. Behavior-modifying psychological treatment and training are frequently adjunctive therapy used in association with pharmaceutical agents. There is a need for a therapy having a more desirable side effect profile, to relieve opioid addiction and withdrawal symptoms.
- Ethanol is probably the most frequently used and abused depressant in most cultures and a major cause of morbidity and mortality.
- Repeated intake of large amounts of ethanol can affect nearly every organ system in the body, particularly the gastrointestinal tract, cardiovascular system, and the central and peripheral nervous systems.
- Gastrointestinal effects include gastritis, stomach ulcers, duodenal ulcers, liver cirrhosis, and pancreatitis.
- cardiovascular effects include hypertension, cardiomyopathy and other myopathies, significantly elevated levels of triglycerides and low-density lipoprotein cholesterol. These cardiovascular effects contribute to a marked increase risk of heart disease.
- Peripheral neuropathy may be present as evidenced by muscular weakness, parathesias, and decreased peripheral sensation.
- Central nervous system effects include cognitive deficits, severe memory impairment degenerative changes in the cerebellum, and ethanol-induced persisting amnesiac disorder in which the ability to encode new memory is severely impaired.
- these effects are related to vitamin deficiencies, particularly the B vitamins.
- ethanol dependence or addiction exhibit symptoms and physical changes including dyspepsia, nausea, bloating, esophageal varices, hemorrhoids, tremor, unsteady gait, insomnia, erectile dysfunction, decreased testicular size, feminizing effects associated with reduced testosterone levels, spontaneous abortion, and fetal alcohol syndrome.
- Symptoms associated with ethanol cessation or withdrawal include nausea, vomiting, gastritis, hematemises, dry mouth, puffy blotchy complexion, and peripheral edema.
- ethanol addiction and withdrawal is accomplished by administering a mild tranquilizer such as a chlordiazepoxide.
- vitamins particularly the B vitamins, are also administered.
- magnesium sulfate and/or glucose are also administered.
- Nausea, vomiting and diarrhea are treated symptomatically at the discretion of the attending physician.
- Disulfiram may also be administered for help in maintaining abstinence. If ethanol is consumed while on disulfiram, acetaldehyde accumulates producing nausea and hypotension.
- acetaldehyde accumulates producing nausea and hypotension.
- acetaldehyde accumulates producing nausea and hypotension.
- polydrug or combination drug abuse has been increasing at an alarming rate. For example, cocaine and heroin are often abused together in a drug combination known as a "speedballing.” Such reported increase is believed to be a result of a synergistic effect that increases the euphoria of the user.
- the present invention which addresses the needs of the prior art, provides methods for treating substance addiction and changing addiction-related behavior of a mammal, for example a primate, suffering from substance addiction by administering to the mammal an effective amount of a pharmaceutical composition or medicament including gamma vinylGABA (GVG).
- GVG gamma vinylGABA
- the amount of GVG varies from about
- 15mg/kg to about 2gm/kg preferably from about lOOmg/kg to about 600mg/kg, and most preferably from about 150 mg/kg to about 300 mg/kg.
- the present invention provides a method of eliminating the effects of nicotine addiction by treating a mammal with an effective amount of a composition or medicament including GVG.
- the amount of GVG present in the pharmaceutical composition or medicament is from about 15mg/kg to about 2g/kg. Preferably, 75 mg/kg to about 150 mg/kg, and most preferably from about 18mg/kg to about 20mg/kg.
- the present invention provides a method for changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse which comprises administering to the mammal an effective amount of GVG or a pharmaceutically acceptable salt thereof, wherein the effective amount attenuates the rewarding/incentive effects of drugs of abuse selected from the group consisting of psychostimulants, narcotic analgesics, alcohols, nicotine and combinations thereof in the absence of altering rewarding/incentive effects of food in said mammal.
- the amount of GVG varies from about 15mg/kg to about 2gm/kg, preferably from about 15mg/kg to about 600mg/kg, and most preferably from about 150mg to about 600mg/kg .
- the pharmaceutical composition or medicament useful for the method of the present invention inhibits or eliminates craving experienced by drug addicts for use of the drug of abuse. Moreover, the elimination of behavior associated with drugs of abuse occurs in the absence of an aversive or appetitive response to GVG. Moreover, behavior characteristics associated with dependency on drugs of abuse are reduced or eliminated in the absence of an alteration in the locomotor function of the primate.
- the invention includes a method for changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse which comprises administering to the mammal an effective amount of GVG or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of drugs of abuse.
- the method includes changing addiction-related behavior of a mammal suffering from addiction to drugs of abuse which comprises administering to the mammal an effective amount of a composition or medicament that increases central nervous system GABA levels wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of drugs of abuse.
- the present invention provides a method for changing addiction-related behavior of a mammal suffering from addiction to a combination of abused drugs which comprises administering to the mammal an effective amount of GVG or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof, wherein the effective amount is sufficient to diminish, inhibit or eliminate behavior associated with craving or use of the combination of abused drugs.
- the present invention provides a method for treating a mammal suffering from addiction to abused drugs which comprises administering to the mammal an effective amount of GVG or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof.
- the present invention provides a method for preventing addiction to abused drugs which comprises administering to the mammal an effective amount of GVG or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof.
- Figure 1 is a graph illustrating percent change in distribution volume (DV) for three groups of animals treated with cocaine.
- Figure 2 is a photograph of transaxial parametric DV ratio images of the non- human primate brain at the level of the co ⁇ us striatum.
- Figures 3 A and 3B are graphs illustrating the effects of GVG on locomotor behavior as compared with saline controls.
- Figure 4 is a graph illustrating the effects of GVG on nicotine-induced extracellular dopamine.
- Figure 5 A and 5B are graphs illustrating the effects of nicotine and GVG on extracellular dopamine levels in the nucleus accumbens of freely moving rats.
- Figure 6 is a graph illustrating the effects of methamphetamine on extracellular dopamine levels in the nucleus accumbens of freely moving rats.
- Figure 7 is a graph illustrating the effects of GVG on methamphetamine induced changes in extracellular dopamine levels in the nucleus accumbens of freely moving rats.
- Figure 8 is a graph illustrating the effects of GVG on alcohol induced changes in extracellular dopamine levels in the nucleus accumbens of freely moving rats.
- Figure 9 is a graph illustrating the effects of GVG on cocaine, heroin, and the combination of cocaine and heroin on extracellular dopamine levels in the nucleus accumbens of freely moving rats.
- the present invention provides a highly efficient method for treating substance addiction and for changing addiction-related behavior of mammals, for example primates, suffering from substance addiction.
- addiction-related behavior means behavior resulting from compulsive substance use and is characterized by apparent total dependency on the substance. Symptomatic of the behavior is (I) overwhelming involvement with the use of the drug, (ii) the securing of its supply, and (iii) a high probability of relapse after withdrawal.
- a cocaine user experiences three stages of drug effects.
- the first, acute intoxication (“binge”) is euphoric, marked by decreased anxiety, enhanced self- confidence and sexual appetite, and may be marred by sexual indiscretions, irresponsible spending, and accidents attributable to reckless behavior.
- the second stage, the (“crash”) replaces euphoria by anxiety, fatigue, irritability and depression. Some users have committed suicide during this period.
- the third stage is euphoric, marked by decreased anxiety, enhanced self- confidence and sexual appetite, and may be marred by sexual indiscretions, irresponsible spending, and accidents attributable to reckless behavior.
- the second stage replaces euphoria by anxiety, fatigue, irritability and depression. Some users have committed suicide during this period.
- the third stage is euphoric, marked by decreased anxiety, enhanced self- confidence and sexual appetite, and may be marred by sexual indiscretions, irresponsible spending, and accidents attributable to reckless behavior.
- addiction-related behavior includes behavior associated with all three stages of drug effects.
- Drugs of abuse include but are not limited to psychostimulants, narcotic analgesics, alcohols and addictive alkaloids such as nicotine or combinations thereof.
- Some examples of psychostimulants include but are not limited to amphetamine, dextroamphetamine, methamphetamine, phenmetrazine, diethylpropion, methylphenidate, cocaine and pharmaceutically acceptable salts thereof.
- narcotic analgesics include alfentanyl, alphaprodine, anileridine, bezitramide, codeine, dihydrocodeine, diphenoxylate, ethylmo ⁇ hine, fentanyl, heroin, hydrocodone, hydromo ⁇ hone, isomethadone, levometho ⁇ han, levo ⁇ hanol, metazocine, methadone, metopon, mo ⁇ hine, opium extracts, opium fluid extracts, powdered opium, granulated opium, raw opium, tincture of opium, oxycodone, oxymo ⁇ hone, pethidine, phenazocine, piminodine, racemetho ⁇ han, racemo ⁇ han, thebaine and pharmaceutically acceptable salts thereof.
- Drugs of abuse also include CNS depressants such as barbiturates, chlordiazepoxide, and alcohols such as ethanol, methanol and isopropyl alcohol.
- the method of the present invention can be used to treat mammals addicted to a combination of drugs of abuse.
- the mammal may be addicted to ethanol and cocaine, in which case the present invention is particularly suited for changing addiction-related behavior of the mammal by administering an effective amount of GVG.
- combination of abused drugs include combinations of psychostimulants, narcotic analgesics, alcohols and addictive alkaloids as discussed above.
- combinations of abused drugs include cocaine, nicotine, methamphetamine, ethanol, mo ⁇ hine and heroin.
- a highly abused combination is cocaine and heroin.
- synergy observed with use of a combination of abused drugs For example, when heroin, an indirect dopamine releaser and cocaine, a dopamine reuptake inhibitor, are administered to rodents, a synergistic increase is observed in cerebral NAc dopamine levels. Synergy may be shown, for example, by greater increases in cerebral dopamine levels than would be expected with either drug alone. Preferably, synergy is demonstrated by from about 500% to about 1000% increase in cerebral NAc dopamine levels with the combination of cocaine and heroin as compared to administering either drug alone.
- Compulsive drug use includes three independent components: tolerance, psychological dependence and physical dependence. Tolerance produces a need to increase the dose of the drug after several administration in order to achieve the same magnitude of effect.
- the compulsive use of drugs of abuse or to the combination of abused drugs gives rise to a euphoric stage followed by a stage of craving for the euphoric effects of that drug which leads to use of the drug or combination of drugs.
- the rewarding/incentive effects of drugs of abuse refers to any stimulus (in this case, a drug) that produces anhedonia or increases the probability of a learned response. This is synonymous with reinforcement.
- a stimulus is deemed to be rewarding by using paradigms that are believed to measure reward. This can be accomplished by measuring whether stimuli produce an approach response, also known as an appetitive response or a withdrawal response, as when the animal avoids the stimuli, also known as an aversive response.
- Conditioned place preference is a paradigm which measures approach (appetitive) or withdrawal (aversive) responses.
- rewarding stimuli produce approach behavior.
- one definition of reward is any stimulus that elicits approach behavior.
- the consequences of reward would be to enhance the incentive properties of stimuli associated with the reward.
- Reward can also be measured by determining whether the delivery of a reward is contingent upon a particular response, thereby increasing the probability that the response will reappear in a similar situation, i.e. reinforcement paradigm. For example, a rat pressing a bar a certain number of times for an injection of cocaine is an example of reinforcement.
- Yet another way to measure reward is by determining if a stimulus (e.g. a drug), through multiple pairings with neutral environmental stimuli, can cause the previously neutral environmental stimuli to elicit behavioral effects initially only associated with the drug - this conditioned reinforcement.
- CPP is considered to be a form of conditioned reinforcement.
- the incentive motivational value of a drug can be assessed using conditioned place preference (CPP).
- CPP conditioned place preference
- animals are tested in a drug-free state, to determine whether they prefer an environment in which they previously received the abused drug as compared to an environment in which they previously received saline.
- animals are given a drug in one distinct environment and are given the appropriate vehicle in an alternative environment.
- the CPP paradigm is widely used to evaluate the incentive motivational effects of drugs in laboratory animals (Van Der Kooy, 1995).
- CPP is reflected in an increased duration spent in the presence of the drug-associated stimuli relative to vehicle- injected control animals. It can also be used to asses addiction to a combination of abused drugs.
- craving at the human level is often elicited by sensory stimuli previously associated with drug-taking, conditioning paradigms like CPP may be used to model craving in laboratory animals.
- craving an abused drug or a combination of abused drugs is an intense desire to self-administer the drug(s) previously used by the mammal. The mammal does not need the abused drug to prevent withdrawal symptoms.
- GABA gamma-amino butyric acid
- GABA ⁇ -Amino butyric acid
- microinjection of baclofen into the VTA, acting via these receptor subtypes, can decrease DA concentrations in the NACC.
- pharmacologic manipulation of GABA may effect DA levels in the NACC through modulation of VTA-DA neurons.
- Gamma vinyl GABA may effect DA levels in the NACC through modulation of VTA-DA neurons.
- GVG Gamma vinyl GABA
- GABA-T GABA -transaminase
- GVG is C 6 H u NO 2 or 4-amino-5-hexanoic acid available as Vigabatrin ® from Hoechst Marion Roussel and can be obtained from Marion Merell Dow of Cincinnati, Ohio. GVG does not bind to any receptor or reuptake complex, but increases endogenous intracellular GABA levels by selectively and irreversibly inhibiting GABA-transaminase (GABA-T), the enzyme that normally catabolizes GABA.
- GABA-T GABA-transaminase
- GVG includes the racemic compound or mixture which contains equal amounts of S(+)-gamma- vinyl GABA, and R(-)-gamma vinyl GABA.
- This racemic compound of GVG is available as Vigabatrin ® from Hoechst Marion Roussel and can be obtained from Marion Merell Dow of Cincinnati, Ohio.
- GVG contains asymmetric carbon atoms and thus is capable of existing as enantiomers.
- the present invention embraces any enantiomeric form of GVG including the racemates or racemic mixture of GVG.
- advantages i.e. greater efficacy, to using a particular enantiomer when compared to the other enantiomer or the racemate or racemic mixture in the methods of the instant invention and such advantages can be readily determined by those skilled in the art.
- the enantiomer S(+)-gamma-vinyl GABA is more effective at increasing endogenous intracellular GABA levels than the enantiomer R(-)-gamma-vinyl GABA.
- enantiomers may be synthesized from chiral starting materials, or the racemates may be resolved by conventional procedures which are well known in the art of chemistry such as chiral chromatography, fractional crystallization of diastereomeric salts, and the like.
- GVG or pharmaceutically acceptable salts thereof can be administered systemically by the parenteral and enteral routes which also includes controlled release delivery systems.
- GVG can easily be administered intravenously, or intraperitoneal (i.p.) which is a preferred route of delivery.
- Intravenous or intraperitoneal administration can be accomplished by mixing GVG in a suitable pharmaceutical carrier (vehicle) or excipient as understood by practitioners in the art.
- Oral or enteral use is also contemplated, and formulations such as tablets, capsules, pills, troches, elixirs, suspensions, syrups, wafers, chewing gum and the like can be employed to provide GVG or pharmaceutically acceptable salts thereof.
- pharmaceutically acceptable salts include those salt-forming acids and bases which do not substantially increase the toxicity of the compound.
- suitable salts include salts of mineral acids such as hydrochloric, hydriodic, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids, as well as salts of organic acids such as tartaric, acetic, citric, malic, benzoic, glycollic, gluconic, gulonic, succinic, arylsulfonic, e.g. p-toluenesulfonic acids, and the like.
- mineral acids such as hydrochloric, hydriodic, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acids
- organic acids such as tartaric, acetic, citric, malic, benzoic, glycollic, gluconic, gulonic, succinic, arylsulfonic, e.g. p-toluenesulfonic acids, and the like.
- an effective amount as used herein is that amount effective to achieve the specified result of changing addiction-related behavior of the mammal. It is an amount which will diminish or relieve one or more symptoms or conditions resulting from cessation or withdrawal of the psychostimulant, narcotic analgesic, alcohol, nicotine or combinations thereof. It should be emphasized, however, that the invention is not limited to any particular dose.
- GVG is administered in an amount which has little or no adverse effects.
- the amount administered can be from about 15mg/kg to about 2g/kg or from about 15mg/kg to about 600mg/kg.
- GVG is administered in an amount of from about 15mg/kg to about 2g/kg, preferably from about lOOmg/kg to about
- 300mg/kg or from about 15mg/kg to about 600mg/kg and most preferably from about 150mg/kg to about 300mg/kg or from about 75mg/kg to about 150mg/kg.
- GVG is administered in an amount of from about 15mg/kg to about 2g/kg or from about 15mg/kg to about 600mg/kg, preferably from about lOOmg/kg to about 300mg/kg or from about 150mg/kg to about
- 300mg/kg and most preferably from about 18mg/kg to about 20mg/kg or from about 75mg/kg to about 150mg/kg.
- GVG is administered in an amount of from about 15mg/kg to about 2g/Tcg, preferably from about lOOmg/kg to about 300mg/kg or from about 15mg/kg to about 600mg/kg and most preferably from about 150mg/kg to about 300mg/kg or from about 75mg/kg to about 150mg/kg to a mammal.
- GVG is administered in an amount of from about
- 15mg/kg to about 2g/kg preferably from about lOOmg/kg to about 300mg/kg or from about 15mg/kg to about 600mg/kg and most preferably from about 150mg/kg to about 300mg/kg or from about 75mg/kg to about 150mg/kg to a mammal.
- Mammals include, for example, humans, baboons and other primates, as well as pet animals such as dogs and cats, laboratory animals such as rats and mice, and farm animals such as horses, sheep, and cows.
- Gamma vinyl GABA GABA
- GABA-T GABA -transaminase
- GVG alters cocaine's biochemical effects by causing a dose-dependent and prolonged elevation of extracellular endogenous brain GABA levels.
- GVG significantly attenuated cocaine-induced increases in neostriatal synaptic DA in the primate (baboon) brain as assessed by positron emission tomography (PET) and abolished both the expression and acquisition of cocaine-induced conditioned place preference or CPP. It had no effect, however, on CPP for a food reward or on the delivery of cocaine to the brain locomotor activity.
- compositions or medicaments include drugs which enhance the production or release of GABA in the CNS.
- drugs include, but are not limited to, gabapentin, valproic acid, progabide, gamma-hydroxybutyric acid, fengabine, cetylGABA, topiramate, tiagabine, acamprosate (homo-calcium-acetyltaurine) or a pharmaceutically acceptable salt thereof, or an enantiomer or a racemic mixture thereof.
- the present invention embraces any enantiomeric form of gabapentin, valproic acid, progabide, gamma-hydroxybutyric acid, fengabine, cetylGABA, topiramate, tiagabine, or acamprosate, including the racemates or racemic mixtures thereof.
- the present invention embraces compositions or medicaments which include prodrugs of GABA or drugs which contain GABA as a moiety in its chemical structure. These prodrugs become pharmacologically active when metabolically, enzymatically or non-enzymatically biotransformed or cleaved into GABA in the CNS.
- An example of a prodrug of GABA is progabide which, upon crossing the blood brain barrier, increases endogenous CNS GABA levels.
- GVG Gamma vinyl GABA
- GABA-T GABA-transaminase
- compositions or medicaments which inhibit GABA re- uptake in the CNS are also encompassed by the present invention.
- An example of a GABA re-uptake inhibitor is tiagabine.
- the method of the present invention is useful in potentiating the GABAergic system or increasing extracellular endogenous GABA levels in the CNS.
- enhancing or increasing endogenous CNS GABA levels is defined as increasing or up-regulating GABA levels substantially over normal levels in vivo, within a mammal.
- endogenous CNS GABA levels are enhanced at least by from about 10% to about 600% over normal levels.
- an effective amount as used herein is that amount effective to achieve the specified result of changing addiction-related behavior of the mammal. It is an amount which will diminish or relieve one or more symptoms or conditions resulting from cessation or withdrawal of the psychostimulant, narcotic analgesic, alcohol, nicotine or combinations thereof. It should be emphasized, however, that the invention is not limited to any particular dose.
- an effective amount of gabapentin administered to the mammal is an amount from about 500mg to about 2g/day.
- Gabapentin is available as Neurontin ® from Parke-Davis in the United States.
- An effective amount of valproic acid administered to the mammal is preferably, an amount from about 5mg/kg to about 100 mg/kg/day.
- Valproic acid is available as Depakene ® from Abbott in the United States.
- an effective amount of topiramate administered to the mammal is, for example, an amount from about 50mg to about lg/day.
- Topiramate is available as Topamax ® from McNeil in the United States.
- An effective amount of progabide administered to the mammal is, preferably, an amount from about 250mg to about 2g/day.
- Progabide is available as Gabrene ® from Synthelabo, France.
- the chemical formula of progabide is C ]7 H )6 N 2 O 2 .
- An effective amount of fengabine administered to the mammal is, preferably, an amount from about 250mg to about 4g/day.
- Fengabine is available as SL 79229 from Synthelabo, France.
- the chemical formula of fengabine is C 17 H 17 C 12 NO.
- an effective amount of gamma-hydroxybutyric acid administered to the mammal is an amount from about 5mg/kg to about lOOmg/kg/day.
- Gamma- hydroxybutyric acid is available from Sigma Chemical.
- the chemical formula of gamma-hydroxybutyric acid is C 4 H 7 O 3 Na.
- a graphical method for determining the distribution volume (DV) was developed previously for the kinetic analysis of the [ ⁇ C]-raclopride data.
- the DV ratio was the most reproducible measure of raclopride uptake.
- the ratio is the DV from a receptor-rich region (co ⁇ us striatum) to the DV of a non-receptor region (cerebellum).
- the free receptor concentration was directly proportional to the DV ratio of 1.
- Animal preparation was conducted as detailed previously (Dewey, et al.,
- the statistical analysis was designed to test the hypothesis that (1) the cocaine challenge differed from the test/retest variability of the radio tracer carbon- 11 (performed in the same animals under identical experimental conditions) and (2) the challenge conditions differed from each other.
- the CPP pairings were: 1) saline/saline 2) saline/cocaine 3) GVG/saline 4) saline/cocaine and GVG.
- the animals in each group were randomly assigned to a 2 x
- 16 infrared beams projecting across the cages from left to right and 16 beams from front to back. All the infrared beams are approximately 0.39 cm from the floor.
- mice were placed into two groups.
- group 1 saline (1 ml/kg) was administered via intraperitoneal (i.p.) injection 3 hours prior to i.p. [ ⁇ C]-cocaine administration.
- group 2 GVG (300 mg/kg) was administered via i.p. injection 3 hours prior to i.p. ["C]-cocaine administration. Animals were sacrificed 10 minutes following [ u C]-cocaine injection. Brains were removed and counted for radioactivity.
- group 2 GVG was administered (300 mg/kg) immediately following a baseline scan with labeled cocaine. Approximately 3 hours later, labeled cocaine was again administered and animals were scanned for 60 minutes.
- Microdialysis probes (2.0 mm, Bioanalytical Systems, BAS, West Lafayette, IN) were positioned within the guide cannulae and artificial cerebrospinal fluid (ACSF, 155.0 mM NA " , 1.1 mM Ca 2" , 2.9 mM K ⁇ 132.76 mM Cl ⁇ and 0.83 mM Mg 2 ) was administered through the probe using a CMA/100 microinfusion pump (BAS) at a flow rate of 2.0 ⁇ l/min. Animals were placed in bowls, and probes were inserted and flushed with ACSF overnight. On the day of the study, a minimum of three samples were injected to determine baseline stability. Samples were collected for 20 min.
- the high performance liquid chromatography (HPLC) system consists of a BAS reverse-phase column (3.0 ⁇ C-18), a BAS LC-4C electrochemical transducer with a dual/glassy carbon electrode set at 650 mV, a computer that analyzes data on-line using a commercial software package (Chromograph Bioanalytical Systems), and a dual pen chart recorder.
- the mobile phase flow rate 1.0 ml/min
- the mobile phase consisted of 7.0% methanol, 50 mM sodium phosphate monobasic, 1.0 mM sodium octyl sulfate, and 0.1 mm
- the locomotor response of these animals to stimulant administration was simultaneously quantified using an infrared motion sensor.
- This infrared optical proximity detector monitored movement of the gimbaled arm, an integral component of the freely moving system.
- the digital output of the detector was interfaced with an IBM personal computer and programmed to count both positive and negative arm deflections. These data were collected and totaled using the same temporal sampling protocol used for the dialysis samples. Locomotor activity was then expressed as the number of deflections per sample interval.
- non-human primates received two [ u C]-raclopride injections in accordance with the procedure described in Section 1 of Materials and
- Test/retest primates shown as Group 1 of Table 1 below received placebo (0.9% saline, 1 ml/kg) prior to the second radio tracer injection in order to determine the test/retest variability of this imaging method. TABLE I. Groups and experimental conditions
- [ ⁇ C]-raclopride's binding is dependent upon the concentration of DA in the synaptic cleft. That is, as synaptic DA concentrations decrease, [ ⁇ C]-raclopride binding increases. Conversely, as synaptic DA concentrations increase, [ u C]-raclopride binding decreases.
- the test/retest variability of this imaging method was less than 7 % for group 1. The variability of these PET measurements is consistent with previous values obtained with [ ⁇ C]-raclopride in primates. In Group 2, cocaine produced a greater than 30% reduction in the mean DV ratio (p ⁇ 0.0002, Student's two-tailed t-test, Figure 1).
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M. ( n - 8-10).
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M.
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M.
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M.
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M.
- GVG 150 mg/kg
- GVG 300 mg/kg
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M 2 Monitored animals were injected only with saline.
- GVG on ["C]-cocaine levels in the whole rat and primate brain.
- the levels of [ u C]-cocaine in the brain following intraperitoneal administration of saline and 300 mg/kg GVG were 0.110 ⁇ 0.03 and 0.091 ⁇ 0.02, respectively, which did not statistically differ.
- the pharmacokinetic profile of labeled cocaine binding in the neostriatum was not significantly different from the baseline scan both in terms of absolute uptake as well as clearance.
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M. 2 Monitored animals were injected only with saline. 3 The vehicle was 1 ml/kg of 0.9% NaCl or saline solution. "Significantly less than nicotine/vehicle pairing, p ⁇ 0.01, ANOVA and Student- Newman-Keuls test.
- FIG. 4 shows that GVG (150 mg/kg) blocks nicotine-induced increases in dopamine concentrations in freely moving rats.
- the open circles are control animals.
- the closed circles are from animals treated with GVG 2.5 hours before nicotine.
- baclofen did not affect the maximal responding rate for electrical brain stimulation reward or non-reinforced performance levels, suggesting that baclofen's action was not related to alterations in motor performance/dexterity.
- GVG produced a dose-dependent increase in brain stimulation reward thresholds in male F344 rats (Kushner et al., 1997b), without significant effects on motor performance.
- GVG could increase the metabolism of cocaine, thereby decreasing the amount which reaches the brain and subsequently diminishing its neurochemical effects and ultimately its behavioral actions. However, this is unlikely as brain levels of "C-cocaine were not significantly altered in rats or primates pretreated with GVG
- GVG offers the conceptual advantage of blocking cocaine's incentive motivational and biochemical effects on brain DA by irreversiby inhibiting GABA-T, making the relatively slow de novo synthesis of this enzyme the rate determining step in reversing the inhibition of cocaine's effects.
- a recent case report of a cocaine abuser suggests that gabapentin, an anticonvulsant that also potentiates GABAergic transmission via unknown mechanisms, attenuated cocaine withdrawal and craving.
- sensitization is believed to play a role in the etiology of addiction.
- the effect of saline and 150 mg/kg i.p. of GVG on the expression of cocaine-induced stereotypic behavior following a sensitizing regimen of cocaine was measured in ten freely moving rats.
- nicotine was used as the addictive drug.
- animals of (Group 1) nicotine (0.4 mg/kg, sc) was administered 2.5 hours after GVG (75, 90, 100, or
- mice 150 mg/kg, i.p).
- animals were treated for 21 days with nicotine (0.4 mg/kg, s.c, twice daily).
- GVG 100 mg/kg was administered either 2.5, 12 or 24 hours prior to nicotine (0.4 mg/kg, s.c.) challenge.
- animals were placed in the microdialysis bowls the night before the experiment and artificial cerebrospinal fluid (ACSF) was perfused through the microdialysis probes at a flow rate of 2.0 ⁇ l/min.
- ACSF cerebrospinal fluid
- DA levels were elevated to approximately 200% of basal levels.
- DA returned to basal levels approximately 160 minutes following administration.
- GVG in a dose-dependent fashion inhibited this increase as shown in Figure 5 A.
- GVG had no effect on nicotine-induced increases in DA while at 90 mg/kg, GVG inhibited DA increases by approximately 50% and at 100 mg/kg, it completely abolished any
- the CPP apparatus was made entirely of plexiglass, except for the floor in one of the pairing chambers, which was made of a stainless steel plate with holes (0.5 mm in diameter) spaced 0.5 mm from edge to edge.
- the two pairing chambers differed in visual and tactile cues.
- One chamber was entirely light blue with the stainless steel floor and the second chamber was light blue with horizontal black stripes (2.5 cm wide) spaced 3.8 cm apart with a smooth plexiglass floor.
- the two pairing chambers were separated by a third, neutral connecting tunnel (10 x 14 x 36 cm) with clear plexiglass walls and a plexiglass floor.
- the visual and tactile cues were balanced such that no significant side preference was exhibited by animals prior to conditioning.
- the conditioning procedure consisted of 20 sessions carried out consecutively over 20 days. The first three sessions were habituation sessions, during which the animals were handled for 5 minutes per day and exposed to the sights and sounds of the test room. This was followed by 16 sessions of 8 pairings with 1) vehicle/vehicle
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M.
- a total of 8-10 rats were examined for each treatment pairing. All animals received 8 pairings with nicotine and saline prior to the test day. On the test day, animals received either saline or GVG 2.5 hours before being placed into the CPP apparatus.
- Each value represents the mean number of minutes spent in each chamber ⁇ S.E.M.
- a total of 8-10 rats were examined for each treatment pairing. Animals were pretreated with either saline, 37.5 or 75 mg/kg i.p. of GVG and 2.5 hours later, each animal received 0.4 mg/kg s.c. of nicotine, except for one group, which received saline followed by saline treatment (saline/saline pairing). Eight pairings were performed with each animal.
- the saline was 1 ml/kg s.c. of 0.9% saline.
- Group 3 animals received nicotine alone (0.3 mg total, approximately 0.02 mg/kg) 30 minutes prior to the second injection of "C-raclopride.
- GVG was administered intravenously (i.v.) at doses of 100 (Group 4) or 300 mg/kg (Group 5) 2.5 hours prior to nicotine administration.
- Nicotine 0.3 mg total, i.v. was administered 30 minutes prior to the second injection of "C-raclopride.
- Arterial blood samples were obtained throughout the study and selected plasma samples were analyzed for the presence of unchanged "C-raclopride. Animals were not removed from the gantry between isotope injections. Data analysis was performed using the Logan method as detailed previously (Logan, et al., 1990).
- Each primate (n 16) received two "C-raclopride injections. The first served as a baseline for the second that followed GVG, nicotine, or both.
- GVG GVG.
- GVG At a dose of 75 mg/kg, GVG had no effect as nicotine increased extracellular DA by nearly 200% while a dose of 90 mg/kg produced an inhibition of nearly 50%.
- GVG completely abolished nicotine-induced increases in extracellular NACC DA levels.
- an acute injection of GVG 300 mg/kg i.p
- cocaine e.g., nicotine
- the dose of GVG needed to significantly attenuate drug-induced increases in NACC DA levels is dependent not only on the challenge drug used (e.g., cocaine, nicotine), but also on the dose at which the challenge drug is administered.
- the present data further demonstrates that the effectiveness of GVG is related to its dose dependent ability to lower basal DA concentrations prior to drug challenge. For example, the 75 mg/kg dose had no effect on basal DA and on nicotine-induced increases in DA. However, at a dose of either 90 or 100 mg/kg, GVG lowered basal
- GVG had no effect on nicotine-induced increases in NACC DA, when it was administered 24 hours prior to nicotine challenge at the same dose.
- our microdialysis and behavioral data show that even small changes in GABA-T inhibition produced by increasing doses of GVG have a profound effect on the inhibition of nicotine-induced elevations in NACC DA and CPP, respectively.
- nicotine-induced CPP may be species dependent, although this may be confounded by the fact that the studies quoted utilized a different number of pairings.
- the nicotine-induced CPP response reported in the present study is consistent with the notion that nicotine produces a positive effect on incentive motivational behavior.
- GVG abolishes nicotine's behavioral actions by interfering with memory or locomotor activity as GVG does not block food reward or locomotor activity at doses as high as 300 mg/kg (Dewey et al., 1998).
- GVG is not self-administered by rhesus monkeys and animals withdrawn from chronic GVG treatment do not exhibit withdrawal signs or symptoms (Takada, and Yanagita, 1997).
- GVG unlike other drugs used in the pharmacotherapy of certain addictions (e.g. methadone, antabuse), is itself not addicting and does not produce significant aversive effects.
- the attenuation of the acquisition of the CPP response to nicotine by GVG can be inte ⁇ reted as a decrease in the positive incentive value of nicotine.
- microdialysis and PET findings combined with the CPP data show that increases in DA in the NACC alone underlie the addictive liability of drugs of abuse.
- these data combined with the above data for cocaine, show that in vivo microdialysis studies or PET measurements of endogenous DA alone is not necessarily predicative of the efficacy of drugs used to treat diseases thought to be neurotransmitter-specific in nature.
- both the microdialysis data and the PET data clearly demonstrate that at a dose of 100 mg/kg, GVG completely blocked nicotine-induced increases in NACC DA levels, whereas a dose of 75 mg/kg had no effect. In contrast, GVG, at a dose as low as 18.75 mg/kg, completely abolished the expression phase of nicotine-induced CPP while it took a dose of 75 mg/kg to abolish the acquisition phase.
- GVG at a dose of 18.75 mg/kg would not be expected to have any effect on nicotine- induced increases in NACC DA. Furthermore, a similar effect was noted using cocaine where a dose of 300 mg/kg of GVG reduced cocaine-induced increases in
- mice that lack the DA and 5-HT transporters (Sora, et al., 1998; Rocha, et al., 1998).
- neurotransmitters such as 5- MT, acetylcholine, enkephalins and glutamate, play a role in mediating the effects of addictive drugs, including nicotine (Bardo, 1998; Gardner, 1997).
- GVG inhibits the effects of cocaine and nicotine through changes in DA in regions other than the NACC.
- GVG may be inhibiting other neurotransmitters that either modulate DA directly or are themselves involved in mediating the effects of drugs of addiction. Further studies designed to assess the multiple effects of GVG on other neurotransmitters are ongoing.
- baclofen a selective GABAB agonist (Bowery and Pratt, 1992; Ken et al., 1990), into the VTA significantly attenuates the CPP response in animals produced by systemic mo ⁇ hine (Tsuji et al., 1995). Furthermore, systemic administration of baclofen attenuates cocaine self-administration on a progressive ratio and discrete trials schedule (Roberts et al., 1996, 1997).
- GVG attenuates the pharmacologic and behavioral actions of nicotine simply by altering the amount that effectively enters the brain either by changing blood brain barrier permeability or by increasing the systemic rate of metabolism of nicotine. This possibility is unlikely for a number of reasons.
- GVG had no effect on the blood brain barrier transport of "C-cocaine, an alkaloid previously shown to increase NACC DA, in both the rodent or primate brain.
- C-cocaine an alkaloid previously shown to increase NACC DA, in both the rodent or primate brain.
- GVG is excreted primarily in the unchanged form by the kidneys (Grant and Heel, 1991; Porter and Meldrum, 1998), whereas nicotine is metabolized by enzymes in the liver.
- GVG does not interact with the hepatic microsomal enzymes (Grant and Heel, 1991; Porter and Meldrum, 1998) and thus would not induce or inhibit these enzymes.
- this medical imaging technique provides a unique window into the interactions that have been shown to exist between functionally-linked neurotransmitters in both the primate and human brain.
- GVG did not effect the temporal aspects of the response.
- NAc DA reached a maximum concentration within 180 minutes which is identical to the response measured in animals that did not receive GVG prior to challenge.
- Cigarette smokers self- administer intravenous nicotine. Pharmacol. Biochem. Behav., 19: 887-890.
- Nicotine preferentially stimulates dopamine release in the limbic system of the freely moving rat. Eur. J. Pharmacol., 132: 337-338.
- GABAB and dopamine D2 receptors activated by GABAB and dopamine D2 receptors in rat substantia nigra neurones. J. Physiol. 401 : 437-453, 1988.
- Roberts, D.C., Andrews, M.M. (1997) Baclofen suppression of cocaine self- administration: demonstration using a discrete trials procedure.
- Roberts, D.C., Andrews, M.M., Vickers, G.J. (1996) Baclofen attenuates the reinforcing effects of cocaine in animals.
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ509682A NZ509682A (en) | 1998-08-05 | 1999-08-05 | Method of treating addictive behaviour by administering a GVG drug also known as the epileptic vigabatrin (sabril) |
MXPA01001268A MXPA01001268A (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior. |
DE69931789T DE69931789T2 (en) | 1998-08-05 | 1999-08-05 | TREATMENT OF NICOTINE ASK AND SEEK CONDITIONAL BEHAVIOR |
EP99941982A EP1102583B1 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction to nicotine and addiction-related behavior |
JP2000563268A JP2002522383A (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction or addiction-related behavior |
KR1020017001525A KR20010085332A (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addition-related behavior |
CA002339192A CA2339192C (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
IL14106799A IL141067A0 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
BR9912760-1A BR9912760A (en) | 1998-08-05 | 1999-08-05 | Uses of vinylgaba gamma (gvg) and a composition that increases gaba levels in the central nervous system |
AU55452/99A AU772715B2 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
HU0103377A HUP0103377A3 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
PL347912A PL198789B1 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
NO20010539A NO20010539L (en) | 1998-08-05 | 2001-01-31 | Treatment of addiction and addiction-related behavior |
HR20010085A HRP20010085A2 (en) | 1998-08-05 | 2001-02-02 | Treatment of addiction and addiction-related behavior |
CY20061101262T CY1105214T1 (en) | 1998-08-05 | 2006-09-05 | TREATMENT OF NICOTINE ADDICTION AND RELATED ADDICTIVE BEHAVIOR |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/129,253 | 1998-08-05 | ||
US09/129,253 US6057368A (en) | 1998-08-05 | 1998-08-05 | Treatment of addiction and addiction-related behavior |
US09/189,166 | 1998-11-09 | ||
US09/189,166 US6828349B1 (en) | 1998-08-05 | 1998-11-09 | Treatment of addiction and addiction-related behavior |
US09/209,952 US6541520B1 (en) | 1998-08-05 | 1998-12-11 | Treatment of addiction and addiction-related behavior |
US09/209,952 | 1998-12-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000007583A2 true WO2000007583A2 (en) | 2000-02-17 |
WO2000007583A3 WO2000007583A3 (en) | 2000-09-08 |
Family
ID=27383860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/017220 WO2000007583A2 (en) | 1998-08-05 | 1999-08-05 | Treatment of addiction and addiction-related behavior |
Country Status (24)
Country | Link |
---|---|
US (4) | US6541520B1 (en) |
EP (1) | EP1102583B1 (en) |
JP (1) | JP2002522383A (en) |
CN (1) | CN1172663C (en) |
AT (1) | ATE328588T1 (en) |
AU (1) | AU772715B2 (en) |
BR (1) | BR9912760A (en) |
CA (1) | CA2339192C (en) |
CY (1) | CY1105214T1 (en) |
CZ (1) | CZ2001394A3 (en) |
DE (1) | DE69931789T2 (en) |
DK (1) | DK1102583T3 (en) |
ES (1) | ES2267287T3 (en) |
HR (1) | HRP20010085A2 (en) |
HU (1) | HUP0103377A3 (en) |
ID (1) | ID28916A (en) |
IL (1) | IL141067A0 (en) |
MX (1) | MXPA01001268A (en) |
NO (1) | NO20010539L (en) |
NZ (1) | NZ509682A (en) |
PL (1) | PL198789B1 (en) |
PT (1) | PT1102583E (en) |
TW (1) | TWI243674B (en) |
WO (1) | WO2000007583A2 (en) |
Cited By (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000010554A2 (en) * | 1998-08-25 | 2000-03-02 | Sepracor Inc. | Methods and compositions employing optically pure s(+) vigabatrin |
WO2000023059A2 (en) * | 1998-10-20 | 2000-04-27 | Ortho-Mcneil Pharmaceutical, Inc. | Use of anticonvulsant derivatives for treating alcohol dependency |
WO2000050020A2 (en) * | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
WO2000066108A2 (en) * | 1999-04-30 | 2000-11-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cocaine dependency |
WO2001008675A1 (en) * | 1999-07-30 | 2001-02-08 | L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients |
EP1335717A1 (en) * | 2000-10-23 | 2003-08-20 | Brookhaven Science Associates | Treatment of pcp addiction and pcp addiction-related behavior |
US6699840B2 (en) | 2002-02-15 | 2004-03-02 | Transform Pharmaceuticals, Inc. | Controlled- or delayed-release forms of topiramate |
EP1392273A1 (en) * | 2001-05-14 | 2004-03-03 | Brookhaven Science Associates | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg |
EP1392301A2 (en) * | 2001-05-14 | 2004-03-03 | Brookhaven Science Associates | Prevention of addiction in pain management |
US6890951B2 (en) | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
US7041650B2 (en) | 2001-07-09 | 2006-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivative salts |
US7098188B2 (en) | 2001-07-09 | 2006-08-29 | Ortho-Mcneil Pharmaceutical., Inc. | Anticonvulsant derivative salts |
WO2007030697A2 (en) * | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US8084490B2 (en) | 2004-06-16 | 2011-12-27 | Janssen Pharmaceutica N.V. | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US8283478B2 (en) | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
US8362062B2 (en) | 2002-02-15 | 2013-01-29 | Mcneil-Ppc, Inc. | Pharmaceutical compositions with improved dissolution |
US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US8853263B2 (en) | 2006-05-19 | 2014-10-07 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US10633344B2 (en) | 2002-03-01 | 2020-04-28 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192271A1 (en) * | 2003-07-15 | 2005-09-01 | Hythiam, Inc. | Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse |
US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
US7822470B2 (en) * | 2001-10-11 | 2010-10-26 | Osypka Medical Gmbh | Method for determining the left-ventricular ejection time TLVE of a heart of a subject |
US20090088443A1 (en) * | 2002-02-15 | 2009-04-02 | Julius Remenar | Novel crystalline forms of conazoles and methods of making and using the same |
US20100311701A1 (en) * | 2002-02-15 | 2010-12-09 | Transform Pharmaceuticals, Inc | Pharmaceutical Co-Crystal Compositions |
US6797707B2 (en) * | 2002-03-29 | 2004-09-28 | University Of Florida | Antagonists of RF-amide neuropeptides |
US20070059356A1 (en) * | 2002-05-31 | 2007-03-15 | Almarsson Oern | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
US7201920B2 (en) * | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
HUE037643T2 (en) | 2004-06-12 | 2018-09-28 | Collegium Pharmaceutical Inc | Abuse-deterrent drug formulations |
US20060177380A1 (en) * | 2004-11-24 | 2006-08-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20070231268A1 (en) * | 2004-11-24 | 2007-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20080152595A1 (en) * | 2004-11-24 | 2008-06-26 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
US20060110327A1 (en) * | 2004-11-24 | 2006-05-25 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of orally administered pharmaceutical products |
PE20070043A1 (en) * | 2005-05-17 | 2007-02-05 | Wm Internat Ltd | APPARATUS AND METHOD FOR THE NON-CHEMICAL STABILIZATION OF BIO-SOLIDS |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
DE102006016990A1 (en) * | 2006-04-11 | 2007-10-18 | Hermann, Holger Lars, Dr. | Use of baclofen compounds to treat dependence on gamma-hydroxybutyrate or its analogs |
US20100021570A1 (en) * | 2006-06-21 | 2010-01-28 | Harlan Clayton Bieley | Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke |
US20080103111A1 (en) * | 2006-06-21 | 2008-05-01 | Harlan Clayton Bieley | Smoking Cessation Treatment with Appetite Suppression |
US20090239942A1 (en) * | 2006-09-15 | 2009-09-24 | Cloyd James C | Topiramate Compositions and Methods of Making and Using the Same |
US20080194519A1 (en) * | 2006-09-15 | 2008-08-14 | Regents Of The University Of Minnesota | Topiramate compositions and methods for their use |
US20090270438A1 (en) * | 2006-10-18 | 2009-10-29 | Clive Booles | Novel compositions and formulations |
JPWO2008090736A1 (en) * | 2007-01-23 | 2010-05-20 | 公立大学法人名古屋市立大学 | Medicament for the prevention and treatment of Alzheimer type dementia |
EP2182804B1 (en) * | 2007-08-06 | 2017-05-24 | Biotie Therapies, Inc. | Methods for treating dependence |
JP2011500686A (en) * | 2007-10-18 | 2011-01-06 | アイコ バイオテクノロジー | Combined analgesics using opioids and neutral antagonists |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
AU2010300641B2 (en) * | 2009-09-30 | 2016-03-17 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
CN102573821A (en) * | 2009-09-30 | 2012-07-11 | 哈兰·克莱顿·比利 | Smoking cessation with body weight maintenance and nutritional supplement |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
WO2011106692A2 (en) * | 2010-02-25 | 2011-09-01 | Northwestern University | Methods of using (1s, 3s) -3-amino-4-difluoromethylenyl-1-cyclopentanoic acid |
US20120046232A1 (en) * | 2010-06-22 | 2012-02-23 | Medical University Of South Carolina | Compositions and methods for reducing relapse of addictive behavior |
ES2643291T3 (en) | 2010-12-22 | 2017-11-22 | Purdue Pharma L.P. | Controlled release dosage forms with inviolable closure coated |
CA2822769C (en) | 2010-12-23 | 2016-10-04 | Purdue Pharma L.P. | Tamper resistant solid oral dosage forms |
US20140072935A1 (en) * | 2012-09-07 | 2014-03-13 | Tina M. Herron | Method of Regulating Caloric Intake |
US9101636B2 (en) | 2012-11-30 | 2015-08-11 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
KR101840526B1 (en) | 2013-02-05 | 2018-03-20 | 퍼듀 퍼머 엘피 | Tamper resistant pharmaceutical formulations |
US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
AU2015237723B2 (en) | 2014-03-26 | 2018-04-26 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
EP3151906B1 (en) | 2014-06-03 | 2019-12-11 | Pop Test Abuse Deterrent Technology LLC | Drug device configured for wireless communication |
WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
CN114903006A (en) * | 2021-02-09 | 2022-08-16 | 中国科学院脑科学与智能技术卓越创新中心 | Construction method and application of non-human primate substance addiction model |
WO2022235530A1 (en) * | 2021-05-05 | 2022-11-10 | Mind Medicine, Inc. | Mdma enantiomers |
CN115386421A (en) * | 2022-06-23 | 2022-11-25 | 江苏华熙益能生物科技有限公司 | Tobacco essence, preparation method and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0024965A1 (en) * | 1979-07-26 | 1981-03-11 | Merrell Toraude Et Compagnie | Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them |
WO1989003211A1 (en) * | 1987-10-07 | 1989-04-20 | Matrix Technologies, Incorporated | Treatment of cocaine addiction |
EP0509180A1 (en) * | 1991-04-18 | 1992-10-21 | Merrell Dow Pharmaceuticals Inc. | Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3639607A (en) | 1970-11-02 | 1972-02-01 | Jack E Phillips | Method for treating the tobacco smoking habit |
US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
GB2133002B (en) | 1982-12-30 | 1986-01-29 | Merrell Toraude & Co | Process for preparing 4-amino-5-hexenoic acid |
GB8311804D0 (en) | 1983-04-29 | 1983-06-02 | Merrell Toraude & Co | Treatment of seizure disorders and pharmaceutical compositions |
US4595697A (en) | 1984-03-28 | 1986-06-17 | Merrell Dow Pharmaceuticals Inc. | Treatment of seizure disorders and pharmaceutical compositions useful therein |
US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
US5189026A (en) * | 1991-06-07 | 1993-02-23 | Fractal Laboratories, Inc. | Treatment of human diseases involving dysregulation or dysfunction of the nervous system |
GB9125615D0 (en) * | 1991-12-02 | 1992-01-29 | Wyeth John & Brother Ltd | Amines |
US5332736A (en) * | 1993-11-01 | 1994-07-26 | Ortho Pharmaceutical Corporation | Anti-convulsant aroyl aminoacylpyrroles |
US5760049A (en) * | 1997-02-21 | 1998-06-02 | Synapse Pharmaceuticals International, Inc. | Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use |
US5824684A (en) * | 1997-02-21 | 1998-10-20 | Synapse Pharmaceuticals International, Inc. | Method for treating drug and alcohol addiction |
CN1283116A (en) | 1997-10-28 | 2001-02-07 | 先灵公司 | Method of reducing craving in mamals |
AU759756B2 (en) | 1998-10-20 | 2003-05-01 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse |
US6323236B2 (en) | 1999-02-24 | 2001-11-27 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
EP1175211A2 (en) | 1999-04-30 | 2002-01-30 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cocaine dependency |
-
1998
- 1998-12-11 US US09/209,952 patent/US6541520B1/en not_active Expired - Fee Related
-
1999
- 1999-07-28 US US09/362,592 patent/US6593367B1/en not_active Expired - Fee Related
- 1999-08-05 AT AT99941982T patent/ATE328588T1/en active
- 1999-08-05 MX MXPA01001268A patent/MXPA01001268A/en not_active IP Right Cessation
- 1999-08-05 JP JP2000563268A patent/JP2002522383A/en active Pending
- 1999-08-05 WO PCT/US1999/017220 patent/WO2000007583A2/en not_active Application Discontinuation
- 1999-08-05 AU AU55452/99A patent/AU772715B2/en not_active Ceased
- 1999-08-05 ID IDW20010504A patent/ID28916A/en unknown
- 1999-08-05 PL PL347912A patent/PL198789B1/en not_active IP Right Cessation
- 1999-08-05 CZ CZ2001394A patent/CZ2001394A3/en unknown
- 1999-08-05 CA CA002339192A patent/CA2339192C/en not_active Expired - Fee Related
- 1999-08-05 NZ NZ509682A patent/NZ509682A/en not_active IP Right Cessation
- 1999-08-05 DE DE69931789T patent/DE69931789T2/en not_active Expired - Lifetime
- 1999-08-05 HU HU0103377A patent/HUP0103377A3/en unknown
- 1999-08-05 PT PT99941982T patent/PT1102583E/en unknown
- 1999-08-05 CN CNB998117625A patent/CN1172663C/en not_active Expired - Fee Related
- 1999-08-05 BR BR9912760-1A patent/BR9912760A/en not_active Application Discontinuation
- 1999-08-05 DK DK99941982T patent/DK1102583T3/en active
- 1999-08-05 IL IL14106799A patent/IL141067A0/en unknown
- 1999-08-05 ES ES99941982T patent/ES2267287T3/en not_active Expired - Lifetime
- 1999-08-05 EP EP99941982A patent/EP1102583B1/en not_active Expired - Lifetime
- 1999-09-29 TW TW088113319A patent/TWI243674B/en active
-
2000
- 2000-08-09 US US09/635,578 patent/US6323239B1/en not_active Expired - Fee Related
-
2001
- 2001-01-31 NO NO20010539A patent/NO20010539L/en not_active Application Discontinuation
- 2001-02-02 HR HR20010085A patent/HRP20010085A2/en not_active Application Discontinuation
- 2001-02-02 US US09/776,117 patent/US6906099B2/en not_active Expired - Fee Related
-
2006
- 2006-09-05 CY CY20061101262T patent/CY1105214T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0024965A1 (en) * | 1979-07-26 | 1981-03-11 | Merrell Toraude Et Compagnie | Fluorinated methyl beta-alanine derivatives, their preparation and pharmaceutical compositions containing them |
WO1989003211A1 (en) * | 1987-10-07 | 1989-04-20 | Matrix Technologies, Incorporated | Treatment of cocaine addiction |
EP0509180A1 (en) * | 1991-04-18 | 1992-10-21 | Merrell Dow Pharmaceuticals Inc. | Use of GABA-T inhibitors for the treatment of schizophrenia and phencyclidine intoxication |
Non-Patent Citations (12)
Title |
---|
DEWEY ET AL.: "A new GABAergic stategyfor treating cocaine addiction" J. NUCLEAR MED., vol. 39, no. 5suppl., May 1998 (1998-05), pages 99-100, XP000857227 * |
DEWEY ET AL.: "A novel strategy for the treatment of cocaine addiction" SYNAPSE, vol. 30, no. 2, October 1998 (1998-10), pages 119-129, XP000856612 * |
DEWEY ET AL.: "A pharmacologic strategy for the treatment of nicotine addiction" SYNAPSE, vol. 31, no. 1, January 1999 (1999-01), pages 76-86, XP000856613 * |
DEWEY ET AL.: "GABAergic attenuation of cocaine-induced dopamine release and locomotor activity" SYNAPSE, vol. 25, no. 4, 1997, pages 393-398, XP000856597 cited in the application * |
KUSHNER ET AL.: "Comparison of the effects of vigabatrin on cocaine self-administration and food reinforcement" SOC. NEUROSCI. ABSTR., vol. 23, no. 1-2, 1997, page 1942 XP002127040 * |
KUSHNER ET AL.: "Gamma-vinyl GABA attenuats cocaine-induced lowering of brain stimulation reward thresholds" PSYCHOPHARMACOLOGIA, vol. 133, no. 4, 11 November 1997 (1997-11-11), pages 383-388, XP000856604 cited in the application * |
KUSHNER ET AL.: "The irreversible Gamma-aminobutyric acid (GABA) transaminase inhibitor Gamma-vinyl-GABA blocks cocaine self-administration in rats" J. PHARMACOL. EXP. THER., vol. 290, no. 2, 19 July 1999 (1999-07-19), pages 797-802, XP002127042 * |
MORGAN ET AL.: "Effects of pharmacologic increases in brain GABA levels on cocaine-induced changes in extracellular dopamine" SYNAPSE, vol. 28, no. 1, January 1998 (1998-01), pages 60-65, XP002127041 cited in the application * |
MORGAN ET AL.: "Vigabatrin attenuates cocaine-induced changes in brain dopamine concentrations" J. NUCLEAR MED., vol. 38, no. 5suppl., 1997, page 11p XP000857224 * |
ROBERTS ET AL.: "Baclofen attenuates the reinforcing effects of cocaine in rats" NEUROPSYCHOPHARMACOLOGY, vol. 15, no. 4, 1996, pages 417-423, XP002127043 cited in the application * |
TAKADA ET AL.: "Drug dependence study on Vigabatrin in Rhesus monkeys and rats" ARZNEIMITTEL FORSCHUNG, vol. 47, no. 10, October 1997 (1997-10), pages 1087-1092, XP000857211 cited in the application * |
TSUJI ET AL.: "Activation of ventral tegmental GABA-B receptors inhibits morphine-induced place preference in rats" EUR. J. PHARMACOL., vol. 313, no. 3, 17 October 1996 (1996-10-17), pages 169-173, XP002127044 * |
Cited By (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6890951B2 (en) | 1998-08-05 | 2005-05-10 | Brookhaven Science Associates Llc | Treatment of addiction and addiction-related behavior |
WO2000010554A3 (en) * | 1998-08-25 | 2000-11-30 | Sepracor Inc | Methods and compositions employing optically pure s(+) vigabatrin |
WO2000010554A2 (en) * | 1998-08-25 | 2000-03-02 | Sepracor Inc. | Methods and compositions employing optically pure s(+) vigabatrin |
AU759756B2 (en) * | 1998-10-20 | 2003-05-01 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating alcohol dependency, addiction and abuse |
WO2000023059A3 (en) * | 1998-10-20 | 2000-11-23 | Ortho Mcneil Pharm Inc | Use of anticonvulsant derivatives for treating alcohol dependency |
WO2000023059A2 (en) * | 1998-10-20 | 2000-04-27 | Ortho-Mcneil Pharmaceutical, Inc. | Use of anticonvulsant derivatives for treating alcohol dependency |
WO2000050020A3 (en) * | 1999-02-24 | 2000-12-21 | Univ Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
US6323236B2 (en) | 1999-02-24 | 2001-11-27 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
WO2000050020A2 (en) * | 1999-02-24 | 2000-08-31 | University Of Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
WO2000066108A2 (en) * | 1999-04-30 | 2000-11-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating cocaine dependency |
WO2000066108A3 (en) * | 1999-04-30 | 2001-01-11 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in treating cocaine dependency |
WO2001008675A1 (en) * | 1999-07-30 | 2001-02-08 | L. Molteni & C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of agonists of gabab receptors and pharmaceutically acceptable derivates thereof, in the therapy of maintaining nicotine abstinence-dependent patients |
EP1335717A4 (en) * | 2000-10-23 | 2004-06-30 | Brookhaven Science Ass Llc | Treatment of pcp addiction and pcp addiction-related behavior |
JP2004512301A (en) * | 2000-10-23 | 2004-04-22 | ブルックヘヴン サイエンス アソシエイツ | Treatment of PCP addiction and behavior associated with PCP addiction |
EP1335717A1 (en) * | 2000-10-23 | 2003-08-20 | Brookhaven Science Associates | Treatment of pcp addiction and pcp addiction-related behavior |
EP1392273A1 (en) * | 2001-05-14 | 2004-03-03 | Brookhaven Science Associates | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg |
EP1392301A2 (en) * | 2001-05-14 | 2004-03-03 | Brookhaven Science Associates | Prevention of addiction in pain management |
AU2002342533B2 (en) * | 2001-05-14 | 2007-07-05 | Brookhaven Science Associates | Prevention of addiction in pain management |
EP1392301A4 (en) * | 2001-05-14 | 2004-07-14 | Brookhaven Science Ass Llc | Prevention of addiction in pain management |
EP1392273A4 (en) * | 2001-05-14 | 2004-11-24 | Brookhaven Science Ass Llc | Novel treatment for obsessive-compulsive disorder (ocd) and ocd-related disorders using gvg |
US7041650B2 (en) | 2001-07-09 | 2006-05-09 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivative salts |
US7098188B2 (en) | 2001-07-09 | 2006-08-29 | Ortho-Mcneil Pharmaceutical., Inc. | Anticonvulsant derivative salts |
US8362062B2 (en) | 2002-02-15 | 2013-01-29 | Mcneil-Ppc, Inc. | Pharmaceutical compositions with improved dissolution |
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US6699840B2 (en) | 2002-02-15 | 2004-03-02 | Transform Pharmaceuticals, Inc. | Controlled- or delayed-release forms of topiramate |
US7351695B2 (en) | 2002-02-15 | 2008-04-01 | Ortho-Mcneil Pharmaceuticals, Inc. | Topiramate salts and compositions comprising and methods of making and using the same |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
US10633344B2 (en) | 2002-03-01 | 2020-04-28 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
US8084490B2 (en) | 2004-06-16 | 2011-12-27 | Janssen Pharmaceutica N.V. | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
US8283478B2 (en) | 2005-05-20 | 2012-10-09 | Janssen Pharmaceutica Nv | Process for preparation of sulfamide derivatives |
WO2007030697A3 (en) * | 2005-09-07 | 2007-05-03 | Braincells Inc | Modulation of neurogenesis by hdac inhibition |
WO2007030697A2 (en) * | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by hdac inhibition |
US8691867B2 (en) | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8492431B2 (en) | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US8497298B2 (en) | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8853263B2 (en) | 2006-05-19 | 2014-10-07 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
US8809385B2 (en) | 2008-06-23 | 2014-08-19 | Janssen Pharmaceutica Nv | Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU772715B2 (en) | Treatment of addiction and addiction-related behavior | |
Dewey et al. | A pharmacologic strategy for the treatment of nicotine addiction | |
US6890951B2 (en) | Treatment of addiction and addiction-related behavior | |
Mello et al. | Buprenorphine suppresses cocaine self-administration by rhesus monkeys | |
Dewey et al. | A novel strategy for the treatment of cocaine addiction | |
US6828349B1 (en) | Treatment of addiction and addiction-related behavior | |
PT1900362E (en) | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | |
Wolkowitz et al. | A psychopharmacological perspective of cognitive functions: II. Specific pharmacologic agents | |
Glick et al. | 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats | |
AU2002342533B2 (en) | Prevention of addiction in pain management | |
CN1234352C (en) | Treatment of PCP addiction and PCP addiction-related behavior | |
KR20010085332A (en) | Treatment of addiction and addition-related behavior | |
AU2001242011A1 (en) | Treatment of PCP addiction and PCP addiction-related behavior | |
US8258185B2 (en) | Use of neboglamine in the treatment of toxicodependency | |
Ikegami | Involvement of dopamine in the nucleus accumbens and prefrontal cortex in cocaine-associative learning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: P-91/01 Country of ref document: YU Ref document number: 99811762.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 141067 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2001-394 Country of ref document: CZ Ref document number: 55452/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2339192 Country of ref document: CA Ref document number: 2339192 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 509682 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2001/001268 Country of ref document: MX Ref document number: P20010085A Country of ref document: HR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020017001525 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999941982 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999941982 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2001-394 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020017001525 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 55452/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999941982 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020017001525 Country of ref document: KR |